A. Benny

发表

Progression-free survival and local control following stereotactic ablative radiotherapy for up to 5 oligometastases: an analysis from the population-based phase II SABR-5 trial.

N. Chng, S. Tyldesley, Mengxing Liu, 2022, International journal of radiation oncology, biology, physics.